Long Non-Coding Rna As a Potential Diagnostic and Prognostic Biomarker in Melanoma: A Systematic Review and Meta-Analysis Publisher Pubmed



Masrour M¹ ; Khanmohammadi S^{1, 2, 3} ; Fallahtafti P^{1, 4} ; Hashemi SM^{1, 4} ; Rezaei N^{2, 3, 5} Show Affiliations
Source: Journal of Cellular and Molecular Medicine Published:2024

Abstract

Recently, long noncoding RNAs (lncRNAs) have been applied as biomarkers for melanoma patients. In this systematic review and meta-analysis, we investigated the diagnostic and prognostic value of lncRNAs. We used the keywords ‘lncRNA’ and ‘melanoma’ to search databases for studies published before June 14th, 2023. The specificity, sensitivity and AUC were utilized to assess diagnostic accuracy and the prognostic value was assessed using overall survival, progression-free survival and disease-free survival hazard ratios. After screening 1191 articles, we included seven studies in the diagnostic evaluation section and 17 studies in the prognosis evaluation section. The Reitsma bivariate model estimated a cumulative sensitivity of 0.724 (95% CI: 0.659–0.781, p < 0.001) and specificity of 0.812 (95% CI: 0.752–0.859, p < 0.001). The pooled AUC was 0.780 (95% CI: 0.749–0.811, p < 0.0001). The HR for overall survival was 2.723 (95% CI: 2.259–3.283, p < 0.0001). Two studies reported an HR for overall survival less than one, with an HR of 0.348 (95% CI: 0.200–0.607, p < 0.0002). The HR for progression-free survival was 2.913 (95% CI: 2.050–4.138, p < 0.0001). Four studies reported an HR less than one, with an HR of 0.457 (95% CI: 0.256–0.817). The HR for disease-free survival was 2.760 (95% CI: 2.009–3.792, p < 0.0001). In conclusion, the expression of lncRNAs in melanoma patients affects survival and prognosis. LncRNAs can also be employed as diagnostic biomarkers. © 2024 The Authors. Journal of Cellular and Molecular Medicine published by Foundation for Cellular and Molecular Medicine and John Wiley & Sons Ltd.